AnGes Takes Gene Editor Emendo Into Fold For $258m
Attractive Allele-Specific Platform
Japanese firm sees broad promise in already affiliated US bioventure’s platform tech that will help it become a more global player in genetic medicine.
You may also be interested in...
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
Astellas subsidiary says it “remains committed” to on-hold program in high-need disease despite fatal events.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?